Clinician-prescribed therapies · Personally reviewed by your provider
MetabolismGLP-1 receptor agonist

GLP-1 weight management, prescribed personally.*

Semaglutide is the long-acting GLP-1 receptor agonist behind Ozempic and Wegovy. Tides prescribes a compounded formulation with full labs, clinician-managed titration, and quarterly review.

Metabolism
Semaglutide
GLP-1 receptor agonist
Tides · Clinician-Prescribed

Quick read

What it is
A long-acting GLP-1 receptor agonist that signals the brain to lower appetite and helps the pancreas release insulin in response to meals. Same active molecule as Ozempic (type 2 diabetes) and Wegovy (chronic weight management).
Primary benefit
Sustained appetite reduction and meaningful weight loss when paired with a personalized dose titration and ongoing clinical review.
Mechanism
Activates GLP-1 receptors in the brain, gut, and pancreas. The brain effect dampens hunger and slows gastric emptying; the pancreatic effect improves insulin response to meals.
Who it's for
Adults pursuing meaningful weight loss who want a clinically-supervised protocol with full lab panels and dose titration, not a hand-off prescription.
Read the full science

What it does

  • Appetite reduction that holds
    GLP-1 receptor activation in the brain dampens hunger signals and reduces food noise. Once-weekly dosing carries the effect cleanly through the full week.
  • Improved insulin response
    GLP-1 action on pancreatic beta cells improves how cleanly the body handles glucose at meals. A1C and fasting insulin both shift in measurable timeframes.
  • Steady, controlled weight loss
    Reduced calorie intake plus slower gastric emptying drives gradual, sustainable weight reduction. Paired with full labs and quarterly review so the protocol stays calibrated to you.
  • Metabolic markers move with you
    Lipids, blood pressure, and inflammatory markers tend to move in the right direction alongside weight loss. The body composition shift is a downstream effect of the metabolic reset.

How it works

Semaglutide is a long-acting GLP-1 receptor agonist. It binds the GLP-1 receptor in the brain (appetite center), the gut (slows stomach emptying so meals feel filling longer), and the pancreas (improves glucose-responsive insulin release). The same active molecule has been studied for years as Ozempic and Wegovy. Tides prescribes a compounded formulation through a US 503A pharmacy, with full lab panels and clinician-managed dose titration.

Clinical context

Typical dose
4 mg weekly
Range
1–4 mg/week
Route
Subcutaneous
Per vial
50 mg · ~87 days
Required labs
A1C, Lipid Panel, Comprehensive Metabolic Panel, Lipase

Who it's for

  • Meaningful, supervised weight loss
  • Prediabetic A1C or insulin resistance markers
  • Patients who want quarterly clinician review, not a one-time prescription
  • Body composition reset alongside training

Cautions

  • Mandatory titration: every patient starts at 1 mg/week
  • Quarterly clinical review required (every 90 days)
  • Not for personal or family history of medullary thyroid carcinoma

Pairs with

CoQ10
Mitochondrial energy support.
$699LASTS ABOUT 12 WEEKS

Semaglutide compounded vial. Cycle length depends on your prescribed dose — Rachel calibrates the titration to you. Pharmacy and clinician fees included.

Start your intake
Reviewed by Dr. Rachel Deutsch, DNP · US compounding pharmacy · Cancel anytime

* Statements have not been evaluated by the FDA. Semaglutide is prescribed by a licensed clinician based on individual clinical review. Not intended to diagnose, treat, cure, or prevent any disease. See your prescribing clinician for personalized guidance.

GLP-1 weight management, prescribed personally. — Tides